All In Biotech

Drug Trial Radar · NCT01988428

Prehospital Antibiotics Against Sepsis Trial

A Prospective Randomized Controlled Trial to Investigate the Effects of Training Emergency Medical Services (EMS) Personnel in Recognizing and Initiating Treatment in the Prehospital Setting Together With Early Administration of Antibiotics for Patients Suspected of (Severe) Sepsis and Septic Shock

Last checked: Nov 19, 2026Latest source record: Jun 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 2,672 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,672

Actual

Start

Jun 2014

Primary completion

Jun 2017

Study completion Jun 2017

Sponsor

Lead sponsor
Amsterdam UMC, location VUmcAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Stichting Nuts Ohra; Nederlandse Internisten Vereniging ( Dutch Association of Internists)
First posted
Nov 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Sepsis is one of the most frequent reasons for referral to emergency departments (EDs) worldwide. The incidence of sepsis is likely to rise in the upcoming years. Sepsis has a tendency to become more serious when left untreated with a high mortality rate, exceeding even those of myocardial infarction and stroke. Therefore, much effort has been put in to start with appropriate therapy as early as possible. Early goal-directed therapy (EGDT) in the emergency department with fluid resuscitation, administration of vasopressors/vasodilators and intravenous antibiotics in patients with severe sepsis and septic shock has indeed decreased mortality substantially. Emergency medical services (EMS) personnel have already made a significant difference in improving care for patients with acute coronary syndrome, multiple trauma and stroke. Patients with severe sepsis or septic shock could also benefit greatly from timely pre-hospital care. Earlier recognition and initiation of treatment by EMS personnel may improve survival even more. Interestingly, the first hour of ED presentation seems to be the most critical hour. Administration of antibiotics and fluid resuscitation in the pre-hospital setting will reduce the time to administration substantially. In adults, to the best of our knowledge, no studies on the effect of pre-hospital administration of antibiotics have been performed. In children with meningitis, some uncontrolled studies show contradictory results, most probably due to bias by severity. We propose a non-blinded randomised multicentre clinical trial study on the efficacy of early, pre-hospital intravenous administration of broad spectrum antibiotics (ceftriaxone), which are effective against a wide variety of infectious pathogens that cause most common community-acquired infections) in patients referred to the ED with suspected severe sepsis or septic shock. Objective: To evaluate whether early, pre-hospital administration of antibiotics, together with training of ambulance personnel in recognizing and initiating treatment reduces 28-day mortality in patients referred to the ED with suspected severe sepsis or septic shock Study design: Non-blinded randomized multicentre clinical trial nested within a stepped wedge design Study population: All patients above the age of 18 years, with suspected severe sepsis or septic shock and transferred to the ED by ambulance, are eligible for study inclusion Intervention: prehospital antibiotics (ceftriaxone 2000 mg intravenously) Main study parameters/endpoints: 28-day mortality, hospital length of stay, admission to intensive or medium care unit (ICU/MC), time to administration of antibiotics. Follow up of one year. QoL after one month after discharge.

Conditions

  • Sepsis
  • Severe Sepsis
  • Septic Shock

Interventions

  • Ceftriaxone 2000 mgDrug

    Ceftriaxone 2000 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mortalityTime frame: 28 day mortality

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • Meander Medical Center

    Amersfoort, Netherlands

  • Academic Medical Centre

    Amsterdam, Netherlands

  • BovenIJ hospital

    Amsterdam, Netherlands

  • Onze Lieve Vrouwe Gasthuis Oost (former: St. Lucas Andreas Hospital)

    Amsterdam, Netherlands

  • Onze Lieve Vrouwe Gasthuis Oost

    Amsterdam, Netherlands

  • VU medical center

    Amsterdam, Netherlands

  • Rijnstate Hospital

    Arnhem, Netherlands

  • Rode Kruis Hospital

    Beverwijk, Netherlands

  • Amphia Hospital

    Breda, Netherlands

  • Albert Schweitzer Hospital

    Dordrecht, Netherlands

  • Gelderse Vallei

    Ede, Netherlands

  • Catharina Hospital

    Eindhoven, Netherlands

  • Maxima Medical Center

    Eindhoven, Netherlands

  • St.Anna Hospital

    Geldrop, Netherlands

  • Zuyderland Hospital

    Geleen, Netherlands

  • Beatrix Hospital

    Gorinchem, Netherlands

  • Spaarne Gasthuis, Haarlem

    Haarlem, Netherlands

  • Zuyderland Hospital

    Heerlen, Netherlands

  • Elkerliek Hospital

    Helmond, Netherlands

  • Spaarne Gasthuis

    Hoofddorp, Netherlands

  • Maastricht Medical Center

    Maastricht, Netherlands

  • St.Antonius Hospital

    Nieuwegein, Netherlands

  • Canisius Wilhemina Hospital

    Nijmegen, Netherlands

  • Bravis Hospital

    Roosendaal, Netherlands

  • Haven Hospital

    Rotterdam, Netherlands

  • Ikazia Hospital

    Rotterdam, Netherlands

  • Maasstad Hospital

    Rotterdam, Netherlands

  • St.Franciscus Gasthuis

    Rotterdam, Netherlands

  • Vlietland Hospital

    Schiedam, Netherlands

  • Rivierenland Hospital

    Tiel, Netherlands

  • Diakonesse Hospital

    Utrecht, Netherlands

  • University Medical Center, Utrecht

    Utrecht, Netherlands

  • VieCuri Medical Center

    Venlo, Netherlands

  • Amstelland Ziekenhuis

    Amstelveen, North Holland, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.